Win 18446 - CAS:1477-57-2

您当前的位置：

Win 18446

目录号 : KM19372 CAS No. : 1477-57-2 纯度 : ≥98%

Data Sheet 产品使用指南

Win 18446 是具有口服活性的睾丸特异性的酶 ALDH1a2 的抑制剂，其 IC₅₀ 值为 0.3 μM。Win 18446 可逆的抑制多个物种的精子形成，抑制睾丸内视黄醇 (B1342) 合成视黄酸。

规格	价格	是否有货
50mg		In-stock
100mg	询价	In-stock
200mg	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Dydrogesterone-D6 In-stock
Prostaglandin E1-d4 In-stock
Norcholic acid In-stock
Dicyclohexyl phthalate-3,4,5,6-d4 In-stock
Mebhydrolin napadisylate In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Win 18446 is an orally active testes-specific enzyme ALDH1a2 inhibitor, with an IC₅₀ of 0.3 μM. Win 18446 reversibly inhibits spermatogenesis in many species and inhibits Retinoic acid biosynthesis from Retinol (B1342) within the testes.

体外研究

WIN 18446 (1 μM, 24 h) is able to suppress Stra8 expression in whole-testes cultures that contained both germ and somatic cells.

RT-PCR

Cell Line:	Testes were collected from 2-dpp mice.
Concentration:	1 μM.
Incubation Time:	24 h.
Result:	Results in a VAD-like phenotype in the testis. Alone or in combination with ROL significantly reduced Stra8 expression.

体内研究

Win 18446 (200 mg/kg, Orally for 4, 8, and 16 weeks) significantly reduces intratesticular concentrations of retinoic acid, severely impaired spermatogenesis, and caused infertility.

Animal Model:	Six-month-old male New Zealand white rabbits.
Dosage:	200 mg/kg.
Administration:	Orally for 4, 8, and 16 weeks.
Result:	Resulted in marked suppression of testicular weight over time. Dramatically suppressed spermatogenesis. Significantly reduces intratesticular concentrations of retinoic acid and Stra8 expression and very severely suppresses spermatogenesis and fertility.

分子式

C₁₂H₂₀Cl₄N₂O₂

分子量

366.11

CAS号

1477-57-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

溶解性数据

In Vitro:

DMSO : 125 mg/mL (341.43 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7314 mL	13.6571 mL	27.3142 mL
5 mM	0.5463 mL	2.7314 mL	5.4628 mL
10 mM	0.2731 mL	1.3657 mL	2.7314 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.68 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.68 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。